BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34036395)

  • 1. HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance.
    Zong B; Sun L; Peng Y; Wang Y; Yu Y; Lei J; Zhang Y; Guo S; Li K; Liu S
    Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells.
    Zeng X; Jiang S; Ruan S; Guo Z; Guo J; Liu M; Ye C; Dong J
    Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34080025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.
    Watkins J; Weekes D; Shah V; Gazinska P; Joshi S; Sidhu B; Gillett C; Pinder S; Vanoli F; Jasin M; Mayrhofer M; Isaksson A; Cheang MC; Mirza H; Frankum J; Lord CJ; Ashworth A; Vinayak S; Ford JM; Telli ML; Grigoriadis A; Tutt AN
    Cancer Discov; 2015 May; 5(5):488-505. PubMed ID: 25770156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-1205/DNAJB1 reverses docetaxel chemoresistance in human triple negative breast carcinoma cells via regulation of mutp53/TAp63 signaling.
    Yin Y; Zhang J; Ma T; Chen D; Lu D
    Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(1):37-46. PubMed ID: 35130632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
    Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
    Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of SASS6 reduces growth of MDA‑MB‑231 triple‑negative breast cancer cells through arrest of the cell cycle at the G2/M phase.
    Du L; Jing J; Wang Y; Xu X; Sun T; Shi Y; Wang W; Tian B; Han C; Zhao X; Chang H
    Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33907854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
    Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
    Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
    J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SH003 selectively induces p73‑dependent apoptosis in triple‑negative breast cancer cells.
    Choi EK; Kim SM; Hong SW; Moon JH; Shin JS; Kim JH; Hwang IY; Jung SA; Lee DH; Lee EY; Lee S; Kim H; Kim D; Kim YS; Choi YK; Kim HI; Choi HS; Cho SG; Kim JE; Kim KP; Hong YS; Lee WK; Lee JS; Kim TW; Ko SG; Jin DH
    Mol Med Rep; 2016 Oct; 14(4):3955-60. PubMed ID: 27599791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer.
    Mani C; Acharya G; Saamarthy K; Ochola D; Mereddy S; Pruitt K; Manne U; Palle K
    Breast Cancer Res; 2023 Apr; 25(1):44. PubMed ID: 37081516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of long non-coding RNA HOST2 inhibits the proliferation of triple negative breast cancer via regulation of the let-7b/CDK6 axis.
    Zhang Y; Zhang H; Kang H; Huo W; Zhou Y; Zhang Y
    Int J Mol Med; 2019 Feb; 43(2):1049-1057. PubMed ID: 30483747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.
    Hamurcu Z; Delibaşı N; Geçene S; Şener EF; Dönmez-Altuntaş H; Özkul Y; Canatan H; Ozpolat B
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):415-430. PubMed ID: 29288363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
    Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators.
    Castellanet O; Ahmad F; Vinik Y; Mills GB; Habermann B; Borg JP; Lev S; Lamballe F; Maina F
    Theranostics; 2021; 11(19):9180-9197. PubMed ID: 34646365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells.
    Wu W; Ma J; Shao N; Shi Y; Liu R; Li W; Lin Y; Wang S
    PLoS One; 2017; 12(1):e0169229. PubMed ID: 28046018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
    Sheng J; Xue X; Jiang K
    Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.